BioFactura, a biopharmaceutical development company, has announced that the company has been awarded a US patent covering the core technologies of its proprietary StableFast Biomanufacturing Platform.

The US Patent and Trademark Office allowed 32 claims broadly covering composition of matter, methods, commercial kits, and media formulations. StableFast was commercially launched earlier this year. The company is actively marketing the system to companies developing biopharmaceuticals including novel compounds and biosimilars with a focus on therapeutic monoclonal antibodies.

Darryl Sampey, BioFactura’s president and CEO, said “This patent represents years of innovation and development by the BioFactura team that includes the company's original founders.”“I’d also like to acknowledge the excellent work of our intellectual property legal team at Womble Carlyle. We are proud that the USPTO has allowed such a broad set of claims, and we look forward to bringing the StableFast platform to a range of clients in the private and government sectors seeking to develop and manufacture tomorrow’s lifesaving drugs.”